Pharmaking, a Korean Pharmaceutical Company specialized in hepatoprotective medicine speeds up NASH drug development A local pharmaceutical company, Pharmaking conducts a phase-3 trial on PMK-N01GI1
May 25, 2020, 04:30
Pharmaking, a Korean native pharmaceutical company, is set to become a global pharmaceutical company by developing new non-alcoholic steatohepatitis (NASH).
Pharmaking, which received approval from the Ministry of Food and Drug Safety on August, 2019, is planning to introduce 'PMK-N01GI1 (Component name Oltipraz)', a non-alcoholic fatty liver treatment, to global markets in 2022.
According to a recent study, fatty liver causes chronic damage to liver cells and causes inflammation. Also, fatty liver disease itself can cause hepatic cell carcinoma (HCC) or cause various obesity, diabetes, cardiovascular disease. As a result, various candidate drugs are competing in the clinical stage, with the need for active treatment of fatty liver disease worldwide. Through Phase 2 clinical trials on Oltipraz, Pharmaking succeeded in discovering valid features for the treatment of severe fatty liver, in proving confidence in the efficacy of the drug and the safety of the candidate drug's human body. In particular, it succeeded in finding ways to significantly suppress fat content in patients with severe fatty liver, thereby reducing the risk of cardiovascular disease and progress to infection of fatty liver.
In February 1998, Pamarking launched the Pennel capsule based on a patent for the invention of new drugs for treating liver diseases for the first time in Korea. Pennel capsule is the leading prescription medicine for liver diseases in Korea and is exported to Yemen and Egypt in recognition of its excellence in product not only in Korea but also in the world. Since then, the company has secured technical skills and know-how in the development of liver disease treatments by developing Nissel tablet and UDB capsule.
In addition, the company has recently focused on developing proven new drugs with high effectiveness and safety to compete globally. With the launch of Phase 3 clinical trials for Oltipraz, the company is looking forward to the results of its new drug development. In addition, the company is making efforts to develop treatments for adult diseases such as cancer treatment and diabetes based on its abundant technical skills in developing new and improved drugs using natural substances.
"We will reinvest the profits expected to be secured through the launch of Oltipraz in the future and spend them on developing the second and third new drug pipelines," said Kim Wan-bae, chairman of Pharmaking. "We will establish a research institute specializing in liver and digestive system in the medium and long term to enhance our global competitiveness as a company specializing in new drug development."
For more information on Pharmaking, visit http://pharmaking.co.kr/
Contact : Tel. +82-031-739-3300/ firstname.lastname@example.org
Related Link : http://pharmaking.co.kr/
The HANMIR Online PR News is a go-to source that
focuses on small-medium sized enterprises in South Korea.
Media Contacts +82-(0)2-6265-2100 / email@example.com
+82-(0)2-6265-2100 / firstname.lastname@example.org